Search Results
Feb 23, 2026, 08:06 ET Hach presenta NP6000sc, l'analizzatore di fosfati che ridefinisce l'affidabilità e semplifica la conformità normativa per gli impianti di trattamento delle acque
fosfati NP6000sc introduce una maggiore affidabilità nelle prestazioni di processo grazie a misurazioni continue e precise su tre intervalli (0,015-75 mg/L). In questo modo, gli operatori possono ottenere direttamente nel processo un livello di precisione paragonabile a quello di laboratorio.L'NP6000sc
More news about: Hach
Feb 23, 2026, 08:06 ET Hach presenta el analizador de fosfatos NP6000sc
analizador de fosfatos NP6000sc ofrece mayor confianza en el rendimiento del proceso mediante mediciones continuas y precisas en tres rangos (0,015–75 mg/L), lo que permite a los operadores lograr una precisión de laboratorio directamente en el proceso.El NP6000sc aborda este problema directamente
More news about: Hach
Feb 23, 2026, 08:06 ET Hach dévoile l'analyseur d'ortho-phosphates NP6000sc, redéfinissant la fiabilité et simplifiant la conformité pour les installations de traitement de l'eau.
l'analyseur de phosphate NP6000sc renforce la confiance dans les performances du procédé grâce à une mesure continue et précise sur trois gammes (0,015–75 mg/L), permettant aux opérateurs d'atteindre une précision de niveau laboratoire directement sur le procédé.Le NP6000sc répond à ces enjeux grâce à
More news about: Hach
Feb 23, 2026, 08:00 ET Omalizumab Triggers T Cell Modification, Increasing the Reaction Thresholds to Common Food Allergens
participants passing the 600 mg peanut challenge had lower IL-4⁺peanut-reactive T cell frequencies than those who failed. After Stage 2, in the omalizumab plus placebo OIT group, higher mDC/pDC frequencies in peanut-stimulated cultures were observed by researchers for those passing the 2000 mg challenge compared
More news about: American Academy of Allergy, Asthma & Immunology (AAAAI)
Feb 23, 2026, 08:00 ET ITF Therapeutics LLC Announces Multiple Data Presentations at 2026 MDA Clinical and Scientific Conference
Monitor triglycerides at 1 month, 3 months, 6 months, and then every 6 months thereafter. Modify the dosage if fasting triglycerides are verified >300 mg/dL. Treatment with DUVYZAT should be discontinued if triglycerides remain elevated despite adequate dietary intervention and dosage adjustment. Gastrointestinal Disturbances:
More news about: ITF Therapeutics LLC
Feb 23, 2026, 07:07 ET RED BULL REVEALS THE NEW RED BULL® SPRING EDITION CHERRY SAKURA
178 countries worldwide, and more than 13.9 billion cans of Red Bull were consumed in 2025 alone. One 8.4 fl oz can of Red Bull Energy Drink contains 80mg of caffeine, about the same as in a home-brewed cup of coffee. For more information, visit
More news about: Red Bull
Feb 22, 2026, 08:00 ET Omalizumab is as Effective as Multi-Food Oral Immunotherapy for Allergenic Food Tolerability
following multi-food oral immunotherapy (mOIT) or omalizumab treatment. Researchers defined the success of DC plans as participants consuming a median of 300 mg/day of allergenic food at three and six months per daily diary records and using study team evaluations conducted over 12 months."The OUtMATCH
More news about: American Academy of Allergy, Asthma & Immunology (AAAAI)
Feb 21, 2026, 08:00 ET TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
1-800-FDA-1088.Dosage Forms and Strengths: TREMFYA® is available as 100 mg/mL and 200 mg/2mL for subcutaneous injection and as a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion.WHAT IS STELARA® (ustekinumab)?STELARA® is
More news about: Johnson & Johnson
Feb 20, 2026, 12:13 ET O ano começou de verdade! Conheça tratamentos que vão cuidar da sua pele em 2026
fundamental consultar um dermatologista que poderá indicar o melhor plano de tratamentos, de acordo com cada caso", explica o dermatologista Bruno Vargas (CRM-MG 38959/ RQE 32477).Nesse contexto, tratamentos que atuam na regeneração profunda da pele se tornam grandes aliados. Sculptra® emerge como uma
More news about: Galderma
Feb 20, 2026, 09:01 ET PRODUCT OF THE YEAR USA UNVEILS 2026 AWARD WINNERS
BeverageProtein Snack | Tyson® Chicken CupsRice | Ben's Original™ Single-Serve Rice CupsSmokeless Tobacco | FRE Lush 15mg Mega PackSpreadable Cheese | Rondelé by PrésidentToothpaste | TheraBreath ToothpasteTopical Pain Relief |
More news about: Product of the Year
Feb 19, 2026, 17:31 ET Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
findings from the first of two pivotal Phase 3 trials in its UP-AA clinical program, assessing the safety and efficacy of upadacitinib (RINVOQ; 15 mg and 30 mg once daily) in adult and adolescent patients with severe alopecia areata, who had a mean baseline SALT score of 83.8, indicating approximately 16%
More news about: DelveInsight Business Research, LLP
Feb 19, 2026, 12:15 ET Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)
reactions, headache, arthralgia, and elevated liver tests.Omvoh injection is available as a 300 mg/15 mL solution in a single-dose vial for intravenous infusion, and as a 100 mg/mL solution or a 200 mg/2 mL solution in a single dose prefilled pen or prefilled syringe for subcutaneous injection. Refer
More news about: Eli Lilly and Company
Feb 19, 2026, 09:00 ET Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects
microphysiological model.Study Design and DosingThykamine™ was evaluated at four low concentrations (0.025, 0.05, 0.1, and 0.2 mg/mL) over a 14-day treatment period in a dynamic, triple-cell liver model incorporating primary human hepatocytes, Kupffer cells, and hepatic stellate cells
More news about: Devonian Health Group Inc.
Feb 19, 2026, 08:00 ET Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres
(NYSE:BHC)(TSX:BHC), and its dental products business, OraPharma, today announced the 25th anniversary milestone of ARESTIN® (minocycline HCl) Microspheres, 1 mg, a locally administered antibiotic used as an adjunct to scaling and root planing (SRP) for the reduction of pocket depth in adult patients with periodontitis.
More news about: Bausch Health Companies Inc.
Feb 19, 2026, 07:00 ET Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update
was 2.5%, 4.1%, and 4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively. Skin CancersIn ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated patients. AlopeciaIn
More news about: Insmed Incorporated
Feb 18, 2026, 19:40 ET Genicom to Showcase High-Temperature UV Sensor Solutions at AFPE 2026 in Shanghai
the event, Genicom will showcase the MG-12 Monitor / LO Probe Series, engineered to deliver reliable and stable UV measurement performance even in extreme industrial heat environments.GaN-Based Technology for High-Temperature ResilienceThe MG-12 Monitor / LO Probe Series incorporates
More news about: Genicom
Feb 18, 2026, 17:00 ET The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
adults with DM1 for six months. Data were assessed from 38 participants who were randomized 3:1 to receive one dose of 1 mg/kg del-desiran, three doses of either 2 mg/kg del-desiran or 4 mg/kg del-desiran (reflected as siRNA dose), or placebo. The primary endpoint of the study was to evaluate the safety and
More news about: Avidity Biosciences, Inc.
Feb 18, 2026, 13:32 ET Kyowa Hakko Clarifies Glutathione Misconceptions with Science-Backed Insights on Quality and Efficacy of its Industry-Leading Setria® Brand
unmatched clinical backing. A six-month Penn State study, published in the European Journal of Nutrition, showed that daily doses of 250 mg or 1,000 mg increased glutathione levels by 30-35% in blood cells and 260% in buccal cells, with functional benefits including a doubling of natural killer
More news about: Kyowa Hakko U.S.A
Feb 18, 2026, 09:32 ET True Citrus Launches Innovative True Lemon Wellness Line for Cravings, Immunity and Energy Support
(120 mg of plant-based caffeine from green tea extract to help avoid crash or jitters, 200mg of L-Theanine, 200mg of GABA and 60mg magnesium to help support sustained focus, mental clarity and overall mood); Vitamin C (100% DV) to energize and support vitality, and 600mg of Balanced
More news about: True Citrus
Feb 18, 2026, 09:00 ET AVEO Oncology, an LG Chem company, Announces Completion of the First Interim Analysis in the Global Phase 3 FIERCE-HN Study
patients with HPV-negative recurrent or metastatic head and neck squamous cellcarcinoma (R/M HNSCC) –– 20mg/kg dose of ficlatuzumab selected for the combination arm officlatuzumab and cetuximab – – Trials in Progress poster
More news about: AVEO, an LG Chem company
Feb 18, 2026, 08:56 ET Bayou City Hemp Launches Funding Round to Fuel 200% Growth and Dominate $30B THC Beverage Boom with Retail Powerhouse Edge
Texas, Florida, Tennessee, and Illinois while turning regulatory challenges into opportunities."The impending federal amendments, setting a 0.4mg total THC per container limit effective November 2026, restrict many intoxicating hemp products, but BCH is positioned as a compliant leader collaborating
More news about: Bayou City Hemp Company
Feb 18, 2026, 07:30 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
immunotherapy. Patients with prior anti-EGFR therapy were excluded. RYBREVANT FASPRO™ was administered every three weeks (Q3W) at 2400 mg, or 3360 mg for patients weighing 80 kg or more. The primary endpoint is overall response rate (ORR) assessed by blinded independent central review (BICR)
More news about: Johnson & Johnson
Feb 18, 2026, 07:00 ET TopGum Brings Beauty-From-Within Supplementation to a Fruity Gummy
supplements.TopGum successfully combined meaningful doses of these two ingredients into a no-added-sugar gummy supplement. Each gummy contains 45mg hyaluronic acid and 200mg collagen peptides, nourishing the skin from within. The collagen is fish-derived, allowing for kosher certification with a neutral flavor
More news about: TopGum Industries, Inc.
Feb 18, 2026, 06:45 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
line at 1-800-222-1222 or go to the nearest hospital emergency room right away. Zepbound injection is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen or single-dose vial. Learn more Zepbound is a prescription medicine. For more
More news about: Eli Lilly and Company
Feb 17, 2026, 11:00 ET FDA Approves FILKRI™ (filgrastim-laha), Accord BioPharma's Biosimilar to NEUPOGEN® (filgrastim)
Stelara® (ustekinumab), HERCESSI™ (trastuzumab-strf), a biosimilar to Herceptin® (trastuzumab), and CAMCEVI® (leuprolide) 42 mg injectable emulsion.6,7 Please refer to the Important Safety Information and full Prescribing Information for these products, and to the Boxed
More news about: Accord BioPharma